Vogt-Koyanagi-Harada-like Syndrome Induced by Checkpoint Inhibitor Cemiplimab

Checkpoint inhibition targeting programmed cell-death protein 1 has demonstrated efficacy for a wide range of indications including cutaneous malignancy. However, immune-related adverse events (irAEs), including infrequent but visually impactful ocular irAEs, require careful consideration of treatme...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Ye, Khan, Farid, Saraiya, Nehali V., Punjabi, Omar S., Gulati, Vikas, Erickson, Alan R., Yeh, Steven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Clinical Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10473029/
https://www.ncbi.nlm.nih.gov/pubmed/37315200
http://dx.doi.org/10.1097/CJI.0000000000000476

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10473029/
https://www.ncbi.nlm.nih.gov/pubmed/37315200
http://dx.doi.org/10.1097/CJI.0000000000000476

Ejemplares similares